Reactive γ-ketoaldehydes promote protein misfolding and preamyloid oligomer formation in rapidly-activated atrial cells

Journal of Molecular and Cellular Cardiology

Volumn 79, Issue , 2015, Pages 295-302

  Sidorova, Tatiana N ^a   Yermalitskaya, Liudmila V ^a   Mace, Lisa C ^a   Wells, K Sam ^a   Boutaud, Olivier ^a   Prinsen, Joseph K ^a   Davies, Sean S ^a   Roberts, L Jackson ^a   Dikalov, Sergey I ^a   Glabe, Charles G ^b   Amarnath, Venkataraman ^a   Barnett, Joey V ^a   Murray, Katherine T ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amyloidosis; Atrial HL 1 cells; Atrial natriuretic peptide; Levuglandin; Oxidant stress; Preamyloid oligomers; ketoaldehyde

Indexed keywords

ALDEHYDE DERIVATIVE; ATRIAL NATRIURETIC FACTOR; CURCUMIN; GAMMA KETOALDEHYDE DERIVATIVE; OLIGOMER; PREAMYLOID OLIGOMER; SALICYLAMINE; SCAVENGER; SUPEROXIDE; UNCLASSIFIED DRUG; ALDEHYDE; AMINE; AMYLOID;

ARTICLE; ATRIAL CELL; CELL ACTIVATION; CELL DAMAGE; CELL STIMULATION; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; HEART ATRIUM; HEART MUSCLE CELL; LIPID PEROXIDATION; OXIDATIVE STRESS; PROTEIN CROSS LINKING; PROTEIN FOLDING; PROTEIN MISFOLDING; TRANSCRIPTION REGULATION; ANIMAL; BIOLOGICAL MODEL; CELL LINE; CYTOSOL; DRUG EFFECTS; HEART PACING; HUMAN; METABOLISM; MOUSE; PATHOLOGY; PROTEIN MULTIMERIZATION;

ALDEHYDES; AMINES; AMYLOID; ANIMALS; ATRIAL NATRIURETIC FACTOR; CARDIAC PACING, ARTIFICIAL; CELL LINE; CURCUMIN; CYTOSOL; HEART ATRIA; HUMANS; MICE; MODELS, BIOLOGICAL; OXIDATIVE STRESS; PROTEIN FOLDING; PROTEIN MULTIMERIZATION; SUPEROXIDES;

EID: 84919884470     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.11.013     Document Type: Article

References (53)

1. Van Wagoner D.R. Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J Cardiovasc Pharmacol 2008, 52:306-313.
2. De Jong A.M., Maass A.H., Oberdorf-Maass S.U., Van Veldhuisen D.J., Van Gilst W.H., Van Gelder I.C. Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation. Cardiovasc Res 2011, 89:754-765.
3. Korantzopoulos P., Kolettis T.M., Galaris D., Goudevenos J.A. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 2007, 115:135-143.
4. Mihm M.J., Yu F., Carnes C.A., Reiser P.J., McCarthy P.M., Van Wagoner D.R., et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001, 104:174-180.
5. Kim Y.M., Guzik T.J., Zhang Y.H., Zhang M.H., Kattach H., Ratnatunga C., et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res 2005, 97:629-636.
6. Dudley S.C., Hoch N.E., McCann L.A., Honeycutt C., Diamandopoulos L., Fukai T., et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation 2005, 112:1266-1273.
7. Savelieva I., Kakouros N., Kourliouros A., Camm A.J. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace 2011, 13:308-328.
8. Yang Z., Shen W., Rottman J.N., Wikswo J.P., Murray K.T. Rapid stimulation causes electrical remodeling in cultured atrial myocytes. J Mol Cell Cardiol 2005, 38:299-308.
9. Mace L.C., Yermalitskaya L.V., Yi Y., Yang Z., Morgan A.M., Murray K.T. Transcriptional remodeling of rapidly stimulated HL-1 atrial myocytes exhibits concordance with human atrial fibrillation. J Mol Cell Cardiol 2009, 47:485-492.
10. Klein W.L., Krafft G.A., Finch C.E. Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci 2001, 24:219-224.
11. Glabe C.G., Kayed R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 2006, 66:S74-S78.
12. Knowles T.P., Vendruscolo M., Dobson C.M. The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol 2014, 15:384-396.
13. Guerrero-Munoz M.J., Castillo-Carranza D.L., Kayed R. Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. Biochem Pharmacol 2014, 88:468-478.
14. Sanbe A., Osinska H., Saffitz J.E., Glabe C.G., Kayed R., Maloyan A., et al. Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc Natl Acad Sci U S A 2004, 101:10132-10136.
15. Wang X., Osinska H., Klevitsky R., Gerdes A.M., Nieman M., Lorenz J., et al. Expression of R120G-αB-crystallin causes aberrant desmin and αB-crystallin aggregation and cardiomyopathy in mice. Circ Res 2001, 89:84-91.
16. Salomon R.G., Miller D.B., Zagorski M.G., Coughlin D.L. Solvent induced fragmentation of prostaglandin endoperoxides. New aldehyde products from PGH2 and novel intramolecular 1,2-hydride shift during endoperoxide fragmentation in aqueous solution. J Am Chem Soc 1984, 106:6049-6060.
17. 2-mediated cytotoxicity. Biochemistry 2006, 45:15756-15767.
18. Salomon R.G., Subbanagounder G., Singh U., O'Neil J., Hoff H.F. Oxidation of low-density lipoproteins produces levuglandin-protein adducts. Chem Res Toxicol 1997, 10:750-759.
19. Iyer R.S., Ghosh S., Salomon R.G. Levuglandin E2 crosslinks proteins. Prostaglandins 1989, 37:471-480.
20. Brame C.J., Salomon R.G., Morrow J.D., Roberts L.J. Identification of extremely reactive gamma-ketoaldehydes (isolevuglandins) as products of the isoprostane pathway and characterization of their lysyl protein adducts. J Biol Chem 1999, 274:13139-13146.
21. 2) accelerates formation of amyloid β1-42 oligomers. J Neurochem 2002, 82:1003-1006.
22. Boutaud O., Andreasson K.I., Zagol-Ikapitte I., Oates J.A. Cyclooxygenase-dependent lipid-modification of brain proteins. Brain Pathol 2005, 15:139-142.
23. Roychowdhury S., McMullen M.R., Pritchard M.T., Li W., Salomon R.G., Nagy L.E. Formation of γ-ketoaldehyde-protein adducts during ethanol-induced liver injury in mice. Free Radic Biol Med 2009, 47:1526-1538.
24. 2-derived levuglandin adducts increase the neurotoxicity of amyloid β1-42. J Neurochem 2006, 96:917-923.
25. Amarnath V., Amarnath K., Amarnath K., Davies S., Roberts L.J. Pyridoxamine: an extremely potent scavenger of 1,4-dicarbonyls. Chem Res Toxicol 2004, 17:410-415.
26. Davies S.S., Bodine C., Matafonova E., Pantazides B.G., Bernoud-Hubac N., Harrison F.E., et al. Treatment with a γ-ketoaldehyde scavenger prevents working memory deficits in hApoE4 mice. J Alzheimers Dis 2011, 27:49-59.
27. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
28. Amarnath V., Amarnath K., Masterson T.S., Davies S., Roberts L.J. A simplified synthesis of the diasteromers of levuglandin E2. Synth Commun 2005, 35:397-408.
29. Davies S.S., Talati M., Wang X., Mernaugh R.L., Amarnath V., Fessel J., et al. Localization of isoketal adducts in vivo using a single-chain antibody. Free Radic Biol Med 2004, 36:1163-1174.
30. Kayed R., Canto I., Breydo L., Rasool S., Lukacsovich T., Wu J., et al. Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Aβ oligomers. Mol Neurodegener 2010, 5:57.
31. Rocken C., Peters B., Juenemann G., Saeger W., Klein H.U., Huth C., et al. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 2002, 106:2091-2097.
32. Leone O., Boriani G., Chiappini B., Pacini D., Cenacchi G., Martin S.S., et al. Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation. Eur Heart J 2004, 25:1237-1241.
33. Epstein J.A. Currying favor for the heart. J Clin Invest 2008, 118:850-852.
34. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005, 280:5892-5901.
35. Willis M.S., Patterson C. Proteotoxicity and cardiac dysfunction-Alzheimer's disease of the heart?. N Engl J Med 2013, 368:455-464.
36. Vitadello M., Ausma J., Borgers M., Gambino A., Casarotto D.C., Gorza L. Increased myocardial GRP94 amounts during sustained atrial fibrillation: a protective response?. Circulation 2001, 103:2201-2206.
37. Yang M., Tan H., Cheng L., He M., Wei Q., Tanguay R.M., et al. Expression of heat shock proteins in myocardium of patients with atrial fibrillation. Cell Stress Chaperones 2007, 12:142-150.
38. Brundel B.J., Henning R.H., Ke L., Van G.I., Crijns H.J., Kampinga H.H. Heat shock protein upregulation protects against pacing-induced myolysis in HL-1 atrial myocytes and in human atrial fibrillation. J Mol Cell Cardiol 2006, 41:555-562.
39. Mucke L., Selkoe D.J. Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2012, 2:a006338.
40. Seldin D.C., Skinner M. Arthritis accompanying systemic diseases. Kelley's Textbook of Rheumatology 2005, 1697-1704. Elsevier Sanders, Philadelphia. E.D. Harris, R.C. Budd, M.C. Genovese, G.S. Firestein, J.S. Sargent, C.B. Sledge (Eds.).
41. Steiner I., Hajkova P. Patterns of isolated atrial amyloid: a study of 100 hearts on autopsy. Cardiovasc Pathol 2006, 15:287-290.
42. Sidorova T.N., Mace L.C., Wells K.S., Yermalitskaya L.V., Su P.F., Shyr Y., et al. Quantitative imaging of preamyloid oligomers, a novel structural abnormality, in human atrial samples. J Histochem Cytochem 2014, 62:479-487.
43. Gianni D., Li A., Tesco G., McKay K.M., Moore J., Raygor K., et al. Protein aggregates and novel presenilin gene variants in idiopathic dilated cardiomyopathy. Circulation 2010, 121:1216-1226.
44. Despa S., Margulies K.B., Chen L., Knowlton A.A., Havel P.J., Taegtmeyer H., et al. Hyperamylinemia contributes to cardiac dysfunction in obesity and diabetes: a study in humans and rats. Circ Res 2012, 110:598-608.
45. Savelieva I., Kakouros N., Kourliouros A., Camm A.J. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace 2011, 13:610-625.
46. Roberts L.J., Oates J.A., Linton M.F., Fazio S., Meador B.P., Gross M.D., et al. The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic Biol Med 2007, 43:1388-1393.
47. Blumberg J.B., Frei B. Why clinical trials of vitamin E and cardiovascular diseases may be fatally flawed. Commentary on "The relationship between dose of vitamin E and suppression of oxidative stress in humans". Free Radic Biol Med 2007, 43:1374-1376.
48. Nigam A., Talajic M., Roy D., Nattel S., Lambert J., Nozza A., et al. Fish oil for the reduction of atrial fibrillation recurrence, inflammation, and oxidative stress. J Am Coll Cardiol 2014, 64:1441-1448.
49. Davies S.S., Amarnath V., Montine K.S., Bernoud-Hubac N., Boutaud O., Montine T.J., et al. Effects of reactive g-ketoaldehydes formed by the isoprostane pathway (isoketals) and cyclooxygenase pathway (levuglandins) on proteasome function. FASEB J 2002, 16:715-717.
50. Murthi K.K., Friedman L.R., Oleinick N.L., Salomon R.G. Formation of DNA-protein cross-links in mammalian cells by levuglandin E2. Biochemistry 1993, 32:4090-4097.
51. Carrier E.J., Amarnath V., Oates J.A., Boutaud O. Characterization of covalent adducts of nucleosides and DNA formed by reaction with levuglandin. Biochemistry 2009, 48:10775-10781.
52. 2-derived adducts of proteins correlate with Alzheimer's disease severity. J Neurochem 2005, 94:1140-1145.
53. Kirabo A., Fontana V., de Faria A.P., Loperena R., Galindo C.L., Wu J., et al. DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest 2014, 124:4642-4656.